Company intelligence / Profile preview

Celgene Quanticel Research

San Francisco, California, United Statesquanticel.com ↗
Ownership
Private
Development stage
Other
01

Overview

Quanticel Pharmaceuticals' proprietary single-cell genomic analysis platform yielded multiple preclinical drug candidates targeting cancer epigenetic regulators; following Celgene's acquisition, these programs were expected to enter the clinic circa 2016. Limited public results on clinical outcomes.

Therapeutic areas
Oncology
Modalities
Small molecule
Industry
Biotech
02

Partnerships

Celgene (R&D and acquisition agreement post-2011 strategic cancer drug discovery collaboration)

Beyond the preview

Go deeper on Celgene Quanticel Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celgene Quanticel Research.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call